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ABSTRACT
Staphylococcus aureus strains with decreased susceptibility to glycopeptides (GISA) have been associated
with increased risk of glycopeptide treatment failure. To assess the prevalence of these strains in
hospitalised patients in Belgium, 455 methicillin-resistant S. aureus (MRSA) isolates collected in 2001
were screened by two assays: (i) growth on vancomycin agar screen (VAS; brain heart infusion agar
(BHI) + vancomycin 6 mg ⁄L); and (ii) a synergy ⁄ antagonism test with aztreonam ⁄ cefazolin on Mu3 agar
(BHI + vancomycin 3 mg ⁄mL). Isolates growing on VAS or Mu3 agar were characterised further by
analysis of population susceptibility proﬁles. MICs of glycopeptides were determined by agar dilution,
broth microdilution and Etest (low and high inocula) methods. The isolates were genotyped by pulsed-
ﬁeld gel electrophoresis (PFGE) and determination of staphylococcal cassette chromosome mec (SCCmec)
type. No GISA isolates were found. Three (0.7%) hetero-vancomycin intermediate S. aureus (hVISA) and
ten (2.2%) hetero-teicoplanin intermediate S. aureus (hTISA) isolates were identiﬁed by population
analysis. All but one hetero-GISA isolate belonged to either epidemic PFGE group A ⁄ SCCmec type I
(69%) or PFGE group D ⁄ SCCmec type I (23%), both of which were resistant to gentamicin. The
sensitivity and speciﬁcity for the detection of hetero-GISA by the two assays were 15.4% and 99.8%,
respectively, for VAS, and 84.6% and 95.9%, respectively, for Mu3. The data indicated that hetero-GISA
strains were uncommon among Belgian MRSA isolates from hospitalised patients. Use of Mu3 agar was
more sensitive, but less speciﬁc, than VAS as a screening method.
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INTRODUCTION
Staphylococcus aureus is a major pathogen respon-
sible for both nosocomial and community-
acquired infections. For the past two decades,
the prevalence of methicillin-resistant S. aureus
(MRSA) has increased dramatically in many parts
of the world. In Europe, considerable variations
in the prevalence of MRSA are observed, ranging
from <2% in Scandinavia and The Netherlands,
to >30% in southern and western European
countries [1]. In Belgium, the proportion of MRSA
among S. aureus isolates from blood culture has
risen from 23% in 1999 to 28% in 2002. Until
now, glycopeptides have been considered as the
treatment of choice for MRSA infections. In 1990,
Kaatz et al. [2] described the ﬁrst case of infection
with a methicillin-susceptible S. aureus isolate
with intermediate susceptibility to teicoplanin
(TISA). Seven years later, the ﬁrst infection
caused by an MRSA isolate with intermediate
susceptibility to vancomycin was reported in
Japan [3]. Since then, at least 20 cases of infection
caused by MRSA with intermediate susceptibility
to both vancomycin and teicoplanin (GISA) have
been reported worldwide [4,5]. In addition to
GISA, strains that are borderline-susceptible to
glycopeptides, but exhibit low-frequency resist-
ance to glycopeptides (10)6 subpopulation;
hetero-GISA) have been described more fre-
quently in Europe, Brazil and Asia [4–7].
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Although their clinical relevance is still ques-
tioned, such strains appear to be associated with a
poor treatment outcome [8,9] and could represent
the ﬁrst step towards the emergence of glyco-
peptide-resistant mutants following further gly-
copeptide exposure.
The objectives of the present study were, ﬁrst,
to determine the prevalence and investigate the
molecular epidemiology of MRSA with reduced
susceptibility to glycopeptides in the national
survey conducted in 2001 in Belgian hospitals,
and second, to compare the diagnostic perform-
ance of two commercially available GISA ⁄hetero-
GISA screening agars.
MATERIALS AND METHODS
Resistance deﬁnitions
A GISA strain was deﬁned as a S. aureus isolate with: (i) a
vancomycin MIC of >4 mg ⁄L and ⁄ or a teicoplanin MIC of
>8 mg ⁄L, and (ii) a population analysis proﬁle similar to that
of the VISA reference strain HIP5827 [10]. A hetero-GISA
(h-GISA) strain was deﬁned as a S. aureus isolate with: (i) a
vancomycin MIC of £4 mg ⁄L and ⁄or a teicoplanin MIC of
£8 mg ⁄L, and (ii) a population analysis proﬁle similar to that
of the hetero-VISA reference strain Mu3 [7].
Bacteria
From January to December 2001, the Belgian MRSA
Reference Laboratory invited all Belgian hospital laborator-
ies (n = 196) to collect ﬁve non-duplicate, consecutive
MRSA isolates from hospitalised patients [11]. Isolates from
both routine clinical specimens and superﬁcial screening
cultures from mucocutaneous sites were included. The
isolates were sent with a patient case-report form recording
age, sex, type of specimen, hospital ward and type of
acquisition (nosocomial or imported). A nosocomial acqui-
sition was deﬁned as acquisition of an MRSA strain at least
48 h after admission. In total, 455 isolates collected from
100 hospitals were conﬁrmed as MRSA by both phenotypic
(coagulase test and growth on agar containing oxacillin
6 mg ⁄L) and genotypic (PCR for the 16S rRNA, mecA and
nuc genes) methods [11].
Antimicrobial susceptibility
MIC determination
MICs were determined by the agar dilution method, according
to NCCLS guidelines [12], for 15 antimicrobial agents: vanco-
mycin, teicoplanin, oxacillin, erythromycin, clindamycin, qui-
nupristin-dalfopristin, ciproﬂoxacin, gentamicin, tobramycin,
minocycline, rifampicin, trimethoprim-sulphamethoxazole,
fusidic acid, linezolid and mupirocin.
Glycopeptide susceptibility testing methods
All isolates were tested on vancomycin agar screen (VAS) and
Mu3 agar (Becton Dickinson, Heidelberg, Germany). Brieﬂy,
for VAS, 10 lL of a 0.5·McFarland suspension was spotted on
to brain heart infusion agar (BHI) supplemented with vanco-
mycin 6 mg ⁄L, and incubated at 35C for a full 24 h [12]. For
Mu3 agar, a 1· McFarland suspension was inoculated on to
BHI agar supplemented with vancomycin 3 mg ⁄L. Disks of
cefazolin (30 lg) and aztreonam (60 lg) (Neo-Sensitabs; Rosco,
Taastrup, Denmark) were placed on the plate. Following
incubation for 48 h at 35C, the plates were examined for an
inhibition zone surrounded by a ring of satellite growth
around the cefazolin disk, and a ring of heavy and conﬂuent
growth around the aztreonam disk [13].
Isolates with a vancomycin and ⁄or teicoplanin MIC of
‡4 mg ⁄L by agar dilution, or which grew on VAS or Mu3 agar,
were characterised further by population analysis, broth
microdilution tests and Etests (AB Biodisk, Solna, Sweden)
with low and high inocula. MICs by the broth microdilution
method were interpreted according to NCCLS recommenda-
tions [12]. Etest MICs were determined by two protocols: (i)
3 mL of a 0.5· McFarland suspension was ﬂooded on to
Mueller–Hinton agar (MH) and incubated for 24 h at 35C [4];
and (ii) the ‘Etest macromethod’, in which 100 lL of a 2·
McFarland suspension was inoculated on to BHI agar and
incubated for 48 h at 35C [14]. For the macromethod, the
glycopeptide MICs were determined according to criteria
provided by the manufacturer [14], in that isolates inhibited by
both vancomycin and teicoplanin at ‡8 mg ⁄L, or by teicopl-
anin alone at ‡12 mg ⁄L, were considered to be putative hetero-
GISA.
For population analysis, 100 lL of an overnight suspension
(2·McFarland) was spread on to BHI agar supplemented with
vancomycin 0, 2, 4, 6 or 8 mg ⁄L, or teicoplanin 0, 4, 6, 8 and
16 mg ⁄L [4]. Colony counts were determined after incubation
for 48 h at 35C. Control strains were included in each
run: namely the vancomycin-susceptible S. aureus strain
ATCC29213, hetero-VISA strain Mu3, and VISA strain
HIP5827 [7,10].
Molecular typing
Chromosomal macrorestriction analysis using SmaI and
pulsed-ﬁeld gel electrophoresis (PFGE) was performed as
described previously [11]. SmaI patterns were normalised
and compared using the Dice coefﬁcient and UPGMA cluster-
ing method with BioNumerics software v.2.5 (Applied
Maths, Sint-Martens-Latem, Belgium). PFGE patterns were
classiﬁed according to the following nomenclature [11]: (i)
groups of patterns differing by ‡6 DNA fragments were
designated by a capital letter (e.g., A); (ii) patterns within a
group that differed by 3–6 DNA fragments were considered
to form a ‘type’ and were designated by a numeral (e.g., A1);
(iii) subtypes comprised any pattern proﬁle within a type,
and were designated by a lowercase letter sufﬁx (e.g., A1a).
Staphylococcal Cassette Chromosome mec (SCCmec) types
were determined for GISA strains by PCR as described
previously [15].
RESULTS
Glycopeptide susceptibility
All isolates were susceptible according to agar
dilution to vancomycin (MICs of 0.25–4 mg ⁄L)
and teicoplanin (MICs of 0.06–8 mg ⁄L). Six (1.3%)
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isolates had vancomycin MICs of 4 mg ⁄L, and 12
(2.6%) isolates had teicoplanin MICs of 4–
8 mg ⁄L. Only three (0.7%) isolates grew on
VAS. Twenty-nine (6.4%) MRSA isolates grew
on Mu3 agar, with an inhibition zone around the
cefazolin disk and enhanced, usually conﬂuent,
growth around the aztreonam disk.
In total, 35 isolates showing either vancomycin
or teicoplanin MICs of ‡4 mg ⁄L, or which grew on
VAS, or which were positive in screening tests on
Mu3 agar, were characterised further by popula-
tion analysis, broth microdilution and Etests.
According to broth microdilution, all isolates were
susceptible to glycopeptides, except one isolate
which had intermediate susceptibility to teicopla-
nin (MIC of 16 mg ⁄L). All isolates were suscept-
ible to vancomycin and teicoplanin according to
the Etest method with a low inoculum. However,
by the Etest macromethod, 12 isolates showed an
MIC of ‡8 mg ⁄L for vancomycin and teicoplanin,
or ‡12 mg ⁄L for teicoplanin alone. Population
analysis conﬁrmed that three (0.7%) isolates had a
heterogeneous-resistant subpopulation for vanco-
mycin and teicoplanin, and ten (2.1%) isolates
had a heterogeneous-resistant subpopulation for
teicoplanin (Table 1; Figs 1 and 2).
The sensitivity and speciﬁcity for h-GISA
detection were 15.4% and 99.8%, respectively,
for VAS, vs. 84.6% and 95.9%, respectively, for
Mu3 agar. The Etest macromethod detected 92%
of h-GISA isolates with 100% speciﬁcity.
Demographic data
The 13 h-GISA isolates were recovered from 12
hospitals located in Brussels (n = 2), Wallonia
(n = 6) and Flanders (n = 4). The median age of
the patients from whom h-GISA were collected
was 70 years (range, 48–90 years), and 85% of the
patients were male. The patients were hospital-
ised in intensive care units (ICUs) (n = 4), surgical
(n = 4), medical (n = 2), geriatric (n = 1) or other
wards (n = 2) (Table 2). The h-GISA isolates were
isolated from wounds and skin (n = 2), the res-
piratory tract (n = 3), blood (n = 2), nares (n = 2)
or other sites (n = 4). Eleven (85%) of these
isolates were acquired nosocomially.
Antimicrobial susceptibility and molecular
typing
All except one of the 13 h-GISA isolates belonged
to PFGE group A (n = 9) or D (n = 3), and carried
Table 1. Glycopeptide MICs and screen agar results of
hGISA isolates (n = 13) from the Belgian National MRSA
Survey 2001
Isolate
VAS
screen
Mu3 agar
screen
Agar
dilution
MIC
(mg ⁄L)
Broth
microdi-
lution
MIC
(mg ⁄L)
Etest
0.5·
McFa
MIC
(mg ⁄L)
Etest
macro-
methodb
MIC
(mg ⁄L)
PAPTP VA TP VA TP TP VA VA
105 + + 1 4 2 16 2 6 8 16 hGISA
124 – – 4 4 2 4 2 4 4 8 hTISA
151 – + 2 1 2 1 2 2 8 8 hGISA
202 – + 2 4 2 8 2 4 4 16 hTISA
209 + – 1 2 2 4 2 4 4 16 hTISA
242 – + 2 2 2 8 2 4 4 16 hTISA
245 – + 2 2 2 8 4 4 4 16 hTISA
254 – + 2 2 2 8 2 4 4 16 hGISA
412 – + 2 2 2 2 2 4 4 16 hTISA
421 – + 2 4 1 4 2 4 4 16 hTISA
469 – + 1 2 2 4 2 4 4 16 hTISA
632 – + 2 8 4 8 2 6 8 16 hGISA
703 – + 2 4 2 8 4 4 4 16 hTISA
VAS, vancomycin agar screen; VA, vancomycin; TP, teicoplanin; +, growth; – no
growth; PAP, population analysis proﬁle a0.5· McFarland suspension used as an
inoculum [4]. b2.0· McFarland suspension used as an inoculum [14].
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Fig. 1. Vancomycin population analysis of hetero-VISA
strains.
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Fig. 2. Teicoplanin population analysis of hetero-VISA
strains.
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SCCmec type I (n = 12) (Table 2). MICs of oxacil-
lin were ‡64 mg ⁄L. All group PFGE A and D
h-GISA isolates were resistant to ciproﬂoxacin,
gentamicin, tobramycin, erythromycin and clin-
damycin (Table 2). All 13 h-GISA isolates were
susceptible to quinupristin-dalfopristin, minocy-
cline, linezolid, fusidic acid, mupirocin, rifampi-
cin and trimethoprim-sulphamethoxazole.
DISCUSSION
Despite extensive glycopeptide susceptibility test-
ing, no GISA strains were recovered in this survey
of 455 MRSA isolates collected from 100 hospitals
during the Belgian national survey. However, a
low prevalence of isolates expressing hetero-
resistance to teicoplanin (2.1%), or to both vanco-
mycin and teicoplanin (0.7%), was found. The
reported prevalence of h-GISA isolates ranges
widely from one study to another, but was simi-
larly low (<1%) in large surveys conducted in the
UK, Italy, USA and Korea [16–19]. In contrast, a
higher prevalence was observed among MRSA
isolates analysed in Japan (5–22%), Germany
(2–14%), The Netherlands (7.6%) and France
(20%) [7,13,20,21], although other studies in
France have reported lower incidences of h-GISA
(0.6–5%) [22,23]. However, such differences may
be more apparent than real because of marked
differences in the study design and laboratory
methods used for screening and conﬁrming the
hetero-resistance phenotype. Moreover, many of
these studies were retrospective and analysed a
limited number of selected isolates. Higher pre-
valence rates of h-GISA were reported in selected
patient populations, e.g. oncology, surgery or ICU
patients, that were more likely to be exposed to
glycopeptide treatment [9,17,24]. Most studies
have reported a higher prevalence of (hetero-)
resistance of S. aureus to teicoplanin than to
vancomycin, even in countries, such as the USA,
where teicoplanin has not yet been licensed for
clinical use [25–27].
In previous reports, GISA and h-GISA strains
described in Europe belonged to a restricted
range of epidemic MRSA strains, such as the UK
EMRSA 15 and 16 strains, and the Brazilian and
Iberian clones [20,25,26,28]. Molecular typing data
from the present survey showed that all except
one h-GISA isolate belonged to PFGE epidemic
groups A or D, and carried SCCmec type I. Both of
these clones had a similar resistance proﬁle
to multiple antimicrobial agents, including ami-
noglycosides and the macrolide-lincosamide-
streptogramin B group. This association between
h-GISA and a multiresistance phenotype has been
reported previously [9,23,27,29]. By multilocus
sequence typing (MLST), PFGE group A SCCmec
type I isolates (n = 24) belong to the ST 247-
MRSA-I clone (the ‘Iberian clone’) which has been
disseminated widely in Europe and North Amer-
ica for an extended period of time [11,30]. In
Belgium, this clone has been responsible for large
hospital outbreaks since 1984, and was recovered
from 80% of hospitals in the early 1990s. In 2001,
this clone appeared to have been displaced by
other epidemic clones, and particularly by new
variants of PFGE group A (types A20 and A21)
that are susceptible to gentamicin and carry a
type IV SCCmec element. By MLST, such strains
belong to the same clonal complex (CC 8), but
differ by two alleles (ST8 vs. ST247). Interestingly,
the present study did not recover any h-GISA
among isolates belonging to gentamicin-suscept-
ible PFGE group A – SCCmec type IV (n = 90). By
MLST, PFGE group D – SCCmec type I isolates
(n = 18) belong to the ST228-MRSA-I clone which
has also been reported in Slovenia and Germany
[30]. The PFGE group A and D SCCmec type I
isolates, which were the main genotypes associ-
ated with the h-GISA phenotype in the present
study, represented <10% of the isolates in the
overall survey.
While GISA strains have been associated
clearly with glycopeptide treatment failure, the
clinical signiﬁcance of h-GISA strains remains
controversial. Some authors suggest that h-GISA
strains could be precursors of GISA strains.
Table 2. Demographic data, molecular typing and resist-
ance patterns for hGISA isolates (n = 13) from the Belgian
National MRSA survey 2001
Isolate/
hospital
Type of
unit
Origin of
specimen Nosocomial
PFGE
type
SCCmec
type
Resistance
pattern
105 ⁄A ICU Nose Yes A4 I OCEClGT
124 ⁄B ICU Respiratory Yes A19 I OCEClGT
151 ⁄C Surgical Other No B2 IV OC
202 ⁄D Other Wound Yes A19 I OCEClGT
209 ⁄E Medical Other Yes D1 I OCEClGT
242 ⁄ F Surgical Respiratory Yes A1 I OCEClGT
245 ⁄ F Other Wound No A3 I OCEClGT
254 ⁄G ICU Respiratory Yes A4 I OCEClGT
412 ⁄H Geriatric Nose Yes D4 I OCEClGT
421 ⁄ I ICU Blood Yes A3 I OCEClGT
469 ⁄ J Surgical Other Yes D2 I OCEClGT
632 ⁄K Surgical Other Yes A1 I OCEClGT
703 ⁄L Medical Blood Yes A1 I OCEClGT
O, oxacillin; C, ciproﬂoxacin; E, erythromycin, Cl, clindamycin; G, gentamicin; T,
tobramycin; ICU, intensive care unit; PFGE, pulsed-ﬁeld gel electrophoresis.
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Moore et al. [31] found that hetero-resistance to
vancomycin was associated with treatment failure
in a rabbit model of endocarditis. In a similar
model, Pavie et al. [32] did not observe the
emergence of a resistant subpopulation following
treatment with vancomycin, in contrast to teicopl-
anin, which seemed to be more prone to select for
resistance [32]. Hetero-resistance has also been
associated with glycopeptide treatment failure
and a higher patient mortality rate [8,9]. How-
ever, a retrospective study of MRSA bacteraemia
showed similar outcomes for patients infected by
MRSA with reduced susceptibility to vancomycin
or by vancomycin-susceptible MRSA [33].
Moreover, hetero-resistance does not seem be a
common cause of persistent or recurrent bacter-
aemia [34]. Further prospective investigations are
needed to better assess the clinical impact of
hetero-resistance to glycopeptides.
Local outbreaks of infection caused by S. aureus
with reduced susceptibility to glycopeptides have
been described in several hospitals [23,35]. Nasal
carriage of these strains has been detected among
ICU staff [36]. In Belgium, an outbreak caused by a
TISA strain has been reported in ICU patients
(37th Interscience Conference on Antimicrobial
Agents and Chemotherapy, abstract J-122).
Among the present collection of isolates, most
(85%) h-GISA were acquired nosocomially. As the
potential for dissemination of h-GISA has been
demonstrated, guidelines for control of nosocomi-
al transmission of MRSA should be followed
strictly whenever such strains are detected.
The major problem encountered by clinical
laboratories is the routine detection of isolates
with reduced susceptibility to glycopeptides. Disk
diffusion susceptibility testing is inadequate for
detection of both GISA and h-GISA [37]. Most
automated systems also fail to recognise staphy-
lococci with reduced susceptibility to glycopep-
tides. The NCCLS recommends the use of BHI
agar plates supplemented with vancomycin
6 mg ⁄L, or MH agar supplemented with vanco-
mycin 5 mg ⁄L for the detection of GISA [38].
However, h-GISA strains can sometimes fail to
grow on these media, as with VAS in the present
study. Hiramatsu et al. [7] recommend the use of
BHI agar supplemented with vancomycin 4 mg ⁄L
for the screening of h-GISA. This lower concen-
tration of vancomycin allows the detection of
h-VISA and VISA isolates, but this method lacks
speciﬁcity [39]. Previous reports have described
synergic activity between vancomycin and many
b-lactams, except aztreonam, against GISA
isolates [13]. The present study tested Mu3 agar
– BHI agar supplemented with vancomycin
3 mg ⁄L – with a modiﬁed disk diffusion method
for detection of antagonism ⁄ synergism with
b-lactams [13]. Of the 29 MRSA isolates showing
enhanced zones of inhibition with a cefazolin
disk, only 11 were conﬁrmed as h-GISA by
population analysis. The Etest macromethod
developed by Walsh et al. [14], with breakpoints
of vancomycin 8 mg ⁄L and teicoplanin 8 mg ⁄L or
teicoplanin 12 mg ⁄L, was found to be sensitive
and speciﬁc for conﬁrmation of h-GISA, but is too
expensive for use in routine screening. Population
analysis of susceptibility proﬁles is the reference
method for conﬁrming hetero-resistance, but is
too laborious and time-consuming for routine use.
In conclusion, a low prevalence of h-GISA was
found among nosocomial MRSA isolates collected
from a large survey of Belgian hospitals in 2001. A
higher proportion of isolates had a subpopulation
resistant to teicoplanin (2.6%) than to vancomycin
(0.7%). These h-GISA isolates were restricted
largely to minor gentamicin-resistant clones. The
Etest macromethod was nearly as accurate for
conﬁrmation of h-GISA isolates as analysis of
population proﬁles. VAS showed a low sensitivity,
and Mu3 a low speciﬁcity, as screening methods.
Further studies should evaluate h-GISA screening
methods and the clinical signiﬁcance of these
isolates in patients treated with glycopeptides.
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